Pentoxyverin: Effectiveness Against Dry Irritating Cough
Pentoxyverin (brand names Sedotussin, Silomat, Wick MediNait Cold Syrup in combination, and generics) is a centrally acting antitussive without opioid effects. In Germany, pentoxyverin is available in liquid formulations such as syrup and drops, as well as in combination preparations as a cold remedy. The substance suppresses the cough reflex in the cough center and is an established option for dry irritating cough without a productive component.
Compared to opioid antitussives such as codeine or dextromethorphan, pentoxyverin has no abuse potential in the classical sense and no respiratory depressant effects at therapeutic doses. This makes it particularly attractive for patients who wish to avoid opioid active substances or for whom codeine is unsuitable due to concomitant medications or comorbidities. For productive cough with mucus production, pentoxyverin is not the first choice because coughing up mucus is an important bronchial cleansing mechanism.
Mechanism of Action
Pentoxyverin acts centrally in the cough center of the medulla oblongata and suppresses there the impulse transmission that leads to the cough reflex. The exact binding site is not definitively clarified, effects at sigma receptors, NMDA receptors, and GABA modulating synapses are suspected. In contrast to opioid antitussives, there is no effect at the mu opioid receptor, which is why no respiratory depression and no classical addiction development occurs.
Additionally, pentoxyverin possesses weak local anesthetic and spasmolytic properties on the bronchial mucosa and bronchial smooth muscle. These components support the cough-suppressing effect, especially in cough-related muscle tension. Pentoxyverin does not reduce bronchial secretion and is therefore not pharmacologically to be understood as a drying agent.
The half-life is approximately 2 to 4 hours, with onset of action after oral administration about 30 minutes. The substance is metabolized hepatically and excreted mainly renally. More detailed pharmacokinetic characterization is limited because pentoxyverin is an older substance and no modern complete pharmacokinetic data sets are available.
Indications
- Dry irritating cough in acute respiratory infections, tracheitis, or pleuritis
- Irritating cough in malignant disease, especially in palliative situations when opioid antitussives are unsuitable
- Irritating cough after bronchoscopy or surgery, short-term for symptom relief
- Adjuvant in cold preparations with additional decongestant, analgesic, or mucolytic components
- Cough at night when sleep is disturbed by irritating cough
Pentoxyverin is not indicated for productive cough with mucus production. Suppressing the urge to cough would be counterproductive. For chronic cough due to reflux, asthma, COPD, or ACE inhibitor therapy, causal treatment is more important than symptomatic cough suppression.
Dosage and Administration
Adults and adolescents from 12 years: 15 to 30 mg three to four times daily orally. Maximum dose 90 mg per day.
Children between 6 and 12 years: 7.5 to 15 mg three to four times daily. Use syrup form or child-appropriate drops, according to dosing instructions on the package insert.
Children between 2 and 6 years: very restrictive use, according to medical prescription in low dose and short-term.
Children under 2 years: not recommended due to risk of respiratory depression in very sensitive patients.
Administration: with or without meals, adequate water. Syrup can be taken undiluted.
Duration of therapy: short-term, generally a maximum of 7 to 14 days. For prolonged cough, medical evaluation of the cause.
Renal impairment: use cautiously with reduced function. Hepatic impairment: lower dose and short duration of therapy recommended for moderate to severe impairment.
Side Effects
Frequently: drowsiness, sleepiness, mild gastrointestinal discomfort with nausea, abdominal pain, or diarrhea.
Occasionally: dizziness, headache, dry mouth, restlessness, allergic skin reactions with itching or rash.
Rarely: bronchospastic reactions, breathing difficulty, hallucinations at very high doses, seizures in individual cases, allergic reactions up to anaphylaxis.
In children: paradoxical reactions with hyperactivity or irritability possible.
In case of overdose: pronounced sedation, confusion, seizures, circulatory depression at very high doses. Treatment is symptomatic.
Drug Interactions
- Other centrally depressant substances (benzodiazepines, Z-substances, opioids, alcohol, first generation antihistamines): enhanced sedation, risk of falls, in rare cases respiratory depression with concomitant medication and pre-existing conditions.
- MAO inhibitors: theoretically enhanced central effects, caution with combined use.
- Mucolytics (acetylcysteine, ambroxol, bromhexine): pharmacologically opposing mechanism of action. A combination usually does not make sense because cough suppression would prevent expectoration.
- Anticholinergics: no specific interaction.
- SSRIs and SNRIs: no relevant interactions known, nevertheless clinical monitoring is advisable.
Special Precautions
Pregnancy: Limited data. For irritating cough, non-medicinal measures should first be exhausted (inhalation with salt water, honey, adequate fluid intake). If medically necessary, use in consultation with the gynecologist or midwife. Breast-feeding: Transfer into breast milk not sufficiently studied, short-term use possible after individual counseling.
Children and adolescents: not recommended in children under 2 years. Preferred non-medicinal cough care in small children.
Elderly patients: caution due to enhanced sedation and fall risk. Lower doses preferred.
Pre-existing conditions: very restrictive use in asthma, COPD, or bronchiectasis because cough suppression reduces expectoration of mucus. In patients with airway secretion, cough suppression is counterproductive and may lead to pneumonia.
When to see a doctor: medical evaluation required for cough over 7 days, bloody sputum, shortness of breath, fever over 38.5 degrees Celsius, weight loss, or persistent symptoms. Chronic cough may be associated with relevant causes such as asthma, reflux, ACE inhibitor cough, COPD, or tumor.
Lifestyle for irritating cough: drink adequately (water or warm tea with honey), inhalation with steam or salt water, humidification of air, sleep position with elevated upper body, avoidance of smoke, cold air, and dry air.
Driving ability: limited in case of pronounced sedation, individual assessment. Check reaction ability before activities requiring increased attention.
You Might Also Be Interested In
- Dextromethorphan, another antitussive with similar profile
- Codeine, opioid antitussive with abuse and respiratory depression potential
- Noscapine, another non-opioid antitussive
- Ambroxol, classic mucolytic for productive cough
- Cineole, herbal secretolytic
Frequently Asked Questions
When should I take pentoxyverin and when mucolytics?
Pentoxyverin is useful for dry irritating cough without mucus. For productive cough with mucus, mucolytics such as acetylcysteine or ambroxol are indicated because expectoration is an important cleansing mechanism. A combination of both is usually not advisable.
How does pentoxyverin differ from codeine?
Both suppress the cough reflex centrally. Codeine acts at the mu opioid receptor and has abuse potential and respiratory depressant effects. Pentoxyverin does not act as an opioid and has no abuse potential and no relevant respiratory depression at therapeutic doses. For patients without indication for opioids, pentoxyverin is often the safer choice.
Does pentoxyverin make you tired?
Yes, many patients experience drowsiness or mild sedation. When taken in the evening, this is often desirable because nocturnal sleep is not disrupted by cough. During the day, reaction ability should be checked before activities requiring increased attention.
How long may I take pentoxyverin?
Generally a maximum of 7 to 14 days. For prolonged cough, medical evaluation of the cause is necessary because chronic cough may indicate relevant conditions such as asthma, reflux, ACE inhibitor side effect, or tumor.
Sources
- Gelbe Liste, Pentoxyverin Active Ingredient Profile
- BfArM, Federal Institute for Drugs and Medical Devices
- AWMF, Guidelines for Acute and Chronic Cough
- EMA, European Medicines Agency
Legal Notice and Disclaimer
The information provided on this page is for general information purposes only and does not constitute medical advice, diagnosis, or treatment recommendation. It does not replace the advice of a licensed physician or pharmacist. Medications should always be used only after consultation in the pharmacy or medical prescription. All information is based on expert information and recognized scientific sources published at the time of creation, the current product information of the manufacturer is always authoritative. Sanoliste assumes no liability for completeness, timeliness, or accuracy of the information presented. In a medical emergency, call the emergency number 112.